OBJECTIVE: To assess the occurrence and development of new peripheral arterial occlusive disease (PAOD), its risk factors, and the outcome in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 130 type 2 diabetic patients (mean age 58 years) were examined at baseline and after a mean follow-up of 11 years (range 7-14). The ankle-brachial index (ABI) and toe-brachial index were used to detect PAOD. Blood and urine samples were taken at baseline, and a history of cardiovascular events was recorded during follow-up. RESULTS: PAOD was diagnosed in 21 (16%) patients at baseline. During follow-up, 21 of 89 (24%) patients developed new PAOD. There were 29 patients who died, 21 (72%) of them from cardiovascular disease. Patients with PAOD suffered an excess mortality compared with patients without PAOD (58 vs. 16%; P < 0.001). Logistic regression analysis showed that PAOD at baseline was associated with age, duration of diabetes, smoking, and urinary albumin excretion rate. Patients who developed new PAOD during follow-up had higher serum LDL cholesterol concentrations and lower HDL cholesterol concentrations and were older than the patients who remained free of PAOD. CONCLUSIONS: Objectively measured PAOD is frequent in type 2 diabetic patients. It presents the early clinical signs of atherosclerosis and is strongly associated with cardiovascular death. The risk factor pattern for PAOD was different at baseline and after a mean follow-up of 11 years. We consider routine ABI measurements and modification of risk factors necessary also in patients with asymptomatic PAOD.
OBJECTIVE: To assess the occurrence and development of new peripheral arterial occlusive disease (PAOD), its risk factors, and the outcome in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 130 type 2 diabeticpatients (mean age 58 years) were examined at baseline and after a mean follow-up of 11 years (range 7-14). The ankle-brachial index (ABI) and toe-brachial index were used to detect PAOD. Blood and urine samples were taken at baseline, and a history of cardiovascular events was recorded during follow-up. RESULTS: PAOD was diagnosed in 21 (16%) patients at baseline. During follow-up, 21 of 89 (24%) patients developed new PAOD. There were 29 patients who died, 21 (72%) of them from cardiovascular disease. Patients with PAOD suffered an excess mortality compared with patients without PAOD (58 vs. 16%; P < 0.001). Logistic regression analysis showed that PAOD at baseline was associated with age, duration of diabetes, smoking, and urinary albumin excretion rate. Patients who developed new PAOD during follow-up had higher serum LDL cholesterol concentrations and lower HDL cholesterol concentrations and were older than the patients who remained free of PAOD. CONCLUSIONS: Objectively measured PAOD is frequent in type 2 diabeticpatients. It presents the early clinical signs of atherosclerosis and is strongly associated with cardiovascular death. The risk factor pattern for PAOD was different at baseline and after a mean follow-up of 11 years. We consider routine ABI measurements and modification of risk factors necessary also in patients with asymptomatic PAOD.
Authors: Bianca Lw Bendermacher; Joep Aw Teijink; Edith M Willigendael; Marie-Louise Bartelink; Harry R Büller; Ron Jg Peters; Jelis Boiten; Machteld Langenberg; Martin H Prins Journal: Br J Gen Pract Date: 2006-12 Impact factor: 5.386
Authors: Mohamed A Elsharawy; Akram H Alkhadra; Mohammed Fakhary A Ibrahim; Fathi Selim; Khairy Hassan; Aymen S Elsaid; Ahmed Bahnassy Journal: Int J Angiol Date: 2008
Authors: F Gerry R Fowkes; Victor Aboyans; Freya J I Fowkes; Mary M McDermott; Uchechukwu K A Sampson; Michael H Criqui Journal: Nat Rev Cardiol Date: 2016-11-17 Impact factor: 32.419
Authors: K Wattanakit; A R Folsom; M H Criqui; H J Kramer; M Cushman; S Shea; A T Hirsch Journal: Atherosclerosis Date: 2008-02-20 Impact factor: 5.162
Authors: Mikael K Poulsen; Jan Erik Henriksen; Jordi Dahl; Allan Johansen; Jacob E Møller; Oke Gerke; Werner Vach; Torben Haghfelt; Henning Beck-Nielsen; Poul Flemming Høilund-Carlsen Journal: J Nucl Cardiol Date: 2009-08-14 Impact factor: 5.952